GGV Capital’s Asia business will sever ties with the firm’s international operation – switching to separate partnerships and a distinct brand – as venture capital continues to feel the impact of the US and China’s conflicting technology agendas.
Hong Kong’s package of incentives for family offices is intended to redress a balance that has swung in favour of Singapore. Geopolitics is dampening its competitive advantages
Concord Healthcare Group, an onshore subsidiary of US-listed Chinese healthcare business Concord Medical, has filed for an IPO in Hong Kong.
Chinese pharmaceutical industry services provider Canton Biologics has completed a CNY 300m (USD 41m) Series C round led by state-owned SDIC Venture Capital.
Chinese private equity firm Hony Capital has filed to raise a special purpose acquisition company (SPAC) in Hong Kong, having previously failed to get traction with a similar structure in the US.
Hong Kong digital life insurance company Bowtie has closed a USD 34.9m Series B round led by the local unit of Sun Life Financial.
Chinese aftermarket car parts supplier Casstime has raised CNY 200m (USD 27.5m) across two tranches of Series D funding from local investors.
BlueRun Ventures China has been rebranded as Lanchi Ventures to differentiate itself from the Silicon Valley-headquartered VC firm with which it shares a name.
Some LPs have increased their return expectations for Chinese private equity, and they are calling on local managers to be more disciplined on entry valuations and more tenacious on exits in the hope that these higher thresholds can be met.
Investors targeting green technology in China are looking beyond saturated areas such as renewable energy projects to opportunities that target unaddressed industry pain points, the AVCJ Private Equity & Venture Forum China 2023 heard.
Global expansion remains a bright spot in China’s investment landscape as private equity firms slow deployment domestically in favour of supporting China-related entrepreneurs or business concepts in other markets, the AVCJ Private Equity & Venture...
C Capital, an investment firm established by Adrian Cheng, scion of Hong Kong’s New World Development, has closed its latest private equity fund with around USD 250m in commitments.
ShawKwei & Partners found its niche in Asia-based industrials businesses with relative cost advantages. Thanks to geopolitics and shifting growth patterns, the GP is now targeting assets in North America
China’s consumer sector is poised for one of its most lucrative vintages with investors able to take advantage of falling valuations, the AVCJ Private Equity & Venture Forum China 2023 heard.
Investors in Chinese healthcare are looking for innovators with global competencies to lead an industry recovery following a challenging past 12 months, the AVCJ Private Equity & Venture Forum China 2023 heard.
CICC Capital had led a USD 60m Series B round for Grit Biotechnology, a Shanghai-based drug developer that is working on pioneering cancer treatments involving tumour-infiltrating lymphocytes (LIT).
Zhaogang, a private equity-backed Chinese B2B steel-trading platform, is on course to become the first company to list in Hong Kong through a merger with a special purpose acquisition company (SPAC).
KKR has agreed to acquire a majority stake in Chinese pharmacy chain Ruirentang Pharmaceutical Group, according to a filing by a local regulator.
The Carlyle Group and Trustar Capital, private equity owners of McDonald’s China, are poised to abandon plans for a single asset continuation fund in favour of exiting part of their holdings and rolling over the rest into other funds.
GTA Semiconductor, a China-based semiconductor foundry specialising in chips for the automotive industry, has raised CNY 13.5bn (USD 1.85bn) in funding from unnamed investors.
TH Capital, a private equity firm that originated from China's Tsinghua University and was formerly known as Tsinghua Holdings Capital, has completed a USD 60m first close on its debut US dollar-denominated fund.
Shanghai-based surgical robot business Ronovo Surgical has raised CNY200m（USD 27m）in an extended pre-Series B round led by NRL Capital.
Qiming Venture Partners and OrbiMed Asia Partners have led a USD 32m Series A round for Chinese gene editing therapy start-up Epigenic Therapeutics.
Dida, a PE-backed Chinese car-pooling and ride-hailing platform, has filed to list in Hong Kong – for the fourth time in three years. There are records of lapsed registrations from 2020, 2021, and earlier in 2023.